Page last updated: 2024-12-08

furagin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Furagin: Nitrofuran derivative anti-infective agent used for urinary tract infections. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

furagin : An imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [3-(5-nitro-2-furyl)prop-2-en-1-ylidene]amino group (the configuration of the C=C and C=N bonds in the grouping that links the two heterocycles is not specified). A nitrofuran antibiotic with properties similar to nitrofurantoin, furagin is used in the treatment of urinary tract infections. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6870646
CHEMBL ID3707254
SCHEMBL ID3194895
SCHEMBL ID17292896
MeSH IDM0008895

Synonyms (49)

Synonym
AKOS005444359
HY-77036
1-((3-(5-nitro-2-furyl)allylidene)amino)hydantoin
brn 0307076
ccris 1199
furazidin ,
2,4-imidazolidinedione, 1-((3-(5-nitro-2-furanyl)-2-propenylidene)amino)-
nf 416
furagin
hydantoin, 1-((3-(5-nitro-2-furyl)allylidene)amino)-
1-(3-(5-nitro-2-furyl)-n-2-propenylidine)amino-hydantoin
furazidine
f-35
1-((3-(5-nitro-2-furyl)allylidene)amino)-hydantoin
STK368597
1-{[(1e,2e)-3-(5-nitrofuran-2-yl)prop-2-en-1-ylidene]amino}imidazolidine-2,4-dione
furagin (tn)
D07998
1672-88-4
akritoin
1-[(e)-[(e)-3-(5-nitrofuran-2-yl)prop-2-enylidene]amino]imidazolidine-2,4-dione
1-(((1e,2e)-3-(5-nitrofuran-2-yl)allylidene)amino)imidazolidine-2,4-dione
A810846
unii-k2r4n34y9i
4-24-00-01048 (beilstein handbook reference)
k2r4n34y9i ,
furamag
furaginum
S3709
CS-0798
1-(((e)-3-(5-nitrofuran-2-yl)prop-2-enylidene)amino)imidazolidine-2,4-dione
furazidin [who-dd]
furazidin [mart.]
1-[3-(5-nitro-2-furyl)allylidenamino]hydantoin
SCHEMBL3194895
CHEMBL3707254
SCHEMBL17292896
1-((3-(5-nitro-2-furanyl)-2-propenylidene)amino)-4-imidazolidinedione
1-(3-(5-nitro-2-furyl)-n-2-propenylidine)aminohydantoin
j01xe03
DB13475
furazidine;furazidin
CCG-267084
EX-A1974
1-[(e)-[(z)-3-(5-nitrofuran-2-yl)prop-2-enylidene]amino]imidazolidine-2,4-dione
BS-49182
2,4-imidazolidinedione, 1-[[3-(5-nitro-2-furanyl)-2-propen-1-ylidene]amino]-
bdbm50549808
DTXSID101030908

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The drugs were used in a dosage of 2 mg/kg/day in 2 divided doses for 14 days."( [Comparative efficacy of nitrofurans in children and adolescents with pyelonephritis in presence of crystalluria].
Aver'anova, NI; Balueva, LG; Ivanova, NV, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protein cereblonHomo sapiens (human)IC50 (µMol)1,000.00000.28601.70663.0000AID1685005
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (7)

Processvia Protein(s)Taxonomy
protein ubiquitinationProtein cereblonHomo sapiens (human)
positive regulation of Wnt signaling pathwayProtein cereblonHomo sapiens (human)
negative regulation of protein-containing complex assemblyProtein cereblonHomo sapiens (human)
positive regulation of protein-containing complex assemblyProtein cereblonHomo sapiens (human)
negative regulation of monoatomic ion transmembrane transportProtein cereblonHomo sapiens (human)
locomotory exploration behaviorProtein cereblonHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProtein cereblonHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
protein bindingProtein cereblonHomo sapiens (human)
transmembrane transporter bindingProtein cereblonHomo sapiens (human)
metal ion bindingProtein cereblonHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
nucleusProtein cereblonHomo sapiens (human)
cytoplasmProtein cereblonHomo sapiens (human)
cytosolProtein cereblonHomo sapiens (human)
membraneProtein cereblonHomo sapiens (human)
perinuclear region of cytoplasmProtein cereblonHomo sapiens (human)
Cul4A-RING E3 ubiquitin ligase complexProtein cereblonHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1685005Binding affinity to human CRBN-thalidomide binding domain expressed in Escherichia coli by measuring baseline corrected normalized fluorescence by MST based assay2021ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1
Sweet and Blind Spots in E3 Ligase Ligand Space Revealed by a Thermophoresis-Based Assay.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (48.15)18.7374
1990's4 (14.81)18.2507
2000's4 (14.81)29.6817
2010's5 (18.52)24.3611
2020's1 (3.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (11.43%)5.53%
Reviews1 (2.86%)6.00%
Case Studies3 (8.57%)4.05%
Observational0 (0.00%)0.25%
Other27 (77.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]